New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:11 EDTALKSAlkermes aripiprazole lauroxil data looks good, says Leerink
Leerink says the data Alkermes presented from its Phase III trial of aripiprazole lauroxil for treatment of schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting looks good. The firm expects FDA approval of AL in Q3 of 2015 following a 12-month regulatory review. It maintains an Outperform rating on the stock with a $66 price target.
News For ALKS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
06:14 EDTALKSAlkermes price target raised to $72 from $60 at Citigroup
Subscribe for More Information
December 15, 2014
07:02 EDTALKSAlkermes announces initiation of Phase 1 aripiprazole lauroxil study
Subscribe for More Information
December 8, 2014
08:50 EDTALKSAlkermes price target raised to $63 on pipeline catalysts at Credit Suisse
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use